India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India’s drug quality standards have come under increased scrutiny at home and overseas in recent years after locally made cough syrups were linked to the deaths of children in India and also in countries including Gambia and Uzbekistan
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more.
Unlock these with Subscription
The View From India Looking at World Affairs from the Indian perspective.
First Day First Show News and reviews from the world of cinema and streaming.
Today's Cache Your download of the top 5 technology stories of the day.
Science For All The weekly newsletter from science writers takes the jargon out of science and puts the fun in!
Data Point Decoding the headlines with facts, figures, and numbers
THEdge At the cutting edge of education and careers
Health Matters Ramya Kannan writes to you on getting to good health, and staying there
Gender Agenda Stories from beyond the binary.
The Hindu On Books Books of the week, reviews, excerpts, new titles and features.
Published - October 30, 2026 10:14 pm IST - HYDERABAD
An icon of eye drops.
File | Photo Credit: Getty Images/iStockphotos
Indian drug regulators ordered Sun Pharmaceutical Industries to stop manufacturing, selling and distributing ophthalmic products made at its Assam facility after finding failure in its quality management system, documents reviewed by Reuters showed.
The Central Drugs Standard Control Organisation and the office of Drugs Controller Assam ordered the shutdown on August 20 after a joint federal-state inspection of the facility identified lapses in the system meant to ensure product quality and safety, following Sun Pharma’s move in July to voluntarily recall about 11 eye-care brands.
India’s drug quality standards have come under increased scrutiny at home and overseas in recent years after locally made cough syrups were linked to the deaths of children in India and also in countries including Gambia and Uzbekistan.
The regulatory agencies’ move marks an escalation of the action against Sun Pharma, India’s biggest pharmaceutical firm, which will be unable to continue ophthalmic drug production at the Assam factory until it submits a satisfactory compliance report.
Sun Pharma said previously the site was expected to become one of its largest manufacturing hubs for sterile products in a business identified as a key global growth driver.
The regulator sought more information on the recall of 332 batches of ophthalmic suspension products — liquids used to treat eye conditions — the documents showed.
In an internal notice sent to stockists at the time, the company said it was withdrawing the products as a “precautionary measure.” It remains unclear whether all of the recalled products were contaminated.
Sun Pharma did not publicly disclose details of the recall.
The company has submitted a compliance report in response to the order, which is being reviewed by the regulator, an official familiar with the matter told Reuters on condition of anonymity because they were not authorised to speak to the media.
“We voluntarily initiated a temporary cessation of manufacturing activities and informed the regulators,” Sun Pharma said in a statement on Friday (October 30, 2026), adding that remedial measures have been put in place.
It did not respond to a request for comment on the recall.
The company says on its website it follows a single global quality standard.
Some of the recalled products included Lotepred 1% 5ml eye drops, Nepalact OD eye drops, Nepalact-Z, Brinzotim eye drops 5ml and Depopred 2ml.
The eye drops are used to treat eye inflammation, infections and chronic eye diseases, according to doctors.
It is unclear whether these eye products were exported from India or whether any patients reported any adverse effects.
Reuters found that, based on the product packaging, most of the recalled products were manufactured at the Assam state facility in Kokjhar village.
Reuters could not independently verify whether the 332 batches cited by regulators were related only to the 11 identified brands in the recall notice or included additional brands.
The affected batches could translate into hundreds of thousands of eye-drop bottles, according to industry experts, who declined to be identified because they were not authorised to speak publicly.
Ophthalmology contributes about 3% of Sun Pharma’s domestic revenue, according to its 2025-26 annual report.
It is also one of its key areas for the U.S.
The company reported a drop in second-quarter profit on Friday (October 30) weighed down by a one-time charge related to its acquisition of U.S.-based Organon.
The eye product recall coincided with a patient-safety advisory issued in June by the All India Ophthalmological Society (AIOS), an independent body of eye specialists, warning that certain batches of Predmet eye drops appeared to be contaminated.
“There were some adverse cases of infections reported in patients who used Predmet and we got sealed bottles investigated and found it was contaminated,” Santosh Honavar, a doctor and secretary of AIOS, told Reuters, adding that Sun Pharma had also recalled those Predmet drops.
Sun Pharma did not respond a request for comment on the AIOS advisory.
The regulators issued a show-cause notice to Sun Pharma on August 10, citing the quality management system failures, the documents showed.
Dissatisfied with the company’s response, the regulators ordered a halt to the manufacturing, sale and distribution of all ophthalmic products from the facility.
Full detailed coverage is shown on the council website above. Source attribution: The Hindu – Business.
Back to all council news
